Objetivo
Ebola virus (EBOV), a member of Filoviridae family of viruses, is one of the most dangerous microorganisms in the world, causing severe hemorrhagic fevers in humans and non-human primates with high case fatality. Since its discovery in 1976, five different Ebola virus species have been isolated and over 20 sporadic EBOV outbreaks have occurred, mostly confined to rural areas in East and Central Africa. Hence the disease did not attract much global attention. However, the 2014 Ebola outbreak in West Africa, caused by Ebola Zaire strain, gained widespread attention as it took a different pattern and has reached historic proportions, characterized by a rapid and larger spread beyond Africa, and a greater magnitude than all the other outbreaks combined, underscoring its serious threat to the public health. No vaccines or antiviral drugs currently approved for prevention or treatment of Ebola infections in humans. However, the severity of the recent Ebola outbreak and the potential risk of global spread, has spurred research for the rapid development of safe and effective preventive Ebola vaccine. Such a vaccine, that can rapidly induce strong and long-lasting protective immune responses against all main Ebola strains and that can be readily produce and deployed in the field, is needed to protect people in endemic regions in an event of an outbreak but also to protect healthcare workers caring for Ebola patients, who are at the highest risk of infection even before an outbreak can be identified.
A number of EBOV vaccine candidates are under development and some have been shown to induce protective immune responses against lethal Ebola virus infection in different animal models, including non-human primates. In response to the recent Ebola outbreak, three main promising monovalent vector-based vaccines are being investigated in human clinical trials, demonstrating their safety and immunogenicity and the potential efficacy of a Vesicular Stomatitis Virus-based vaccine
Ámbito científico
- medical and health scienceshealth sciencespublic health
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesebola
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantivirals
Palabras clave
Programa(s)
Tema(s)
Convocatoria de propuestas
H2020-JTI-IMI2-2015-08-single-stage
Consulte otros proyectos de esta convocatoriaRégimen de financiación
RIA - Research and Innovation actionCoordinador
75012 Paris
Francia
Ver en el mapa
Participantes (14)
20251 Hamburg
Ver en el mapa
1870 Monthey
Ver en el mapa
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.
75015 PARIS 15
Ver en el mapa
1011 Lausanne
Ver en el mapa
75794 Paris
Ver en el mapa
Entidad jurídica distinta de un subcontratista que está afiliada o vinculada jurídicamente con un participante. Dicha entidad lleva a cabo su trabajo en las condiciones establecidas en el acuerdo de subvención, proporciona bienes o presta servicios para la acción, pero no firma dicho acuerdo. El tercero acata las normas aplicables a su participante en virtud del acuerdo de subvención en lo que respecta a la subvencionalidad de los costes y el control de los gastos.
75654 Paris
Ver en el mapa
75008 Paris
Ver en el mapa
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.
20359 Hamburg
Ver en el mapa
59037 Lille
Ver en el mapa
91058 Evry
Ver en el mapa
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.
01 Abomey Calavi
Ver en el mapa
14112 DAR ES SALAAM
Ver en el mapa
00149 Roma
Ver en el mapa
00161 Roma
Ver en el mapa